Shen Lian Biomedical: The innovative drug pipeline including monoclonal antibodies for AIDS is independently operated by Shizhiyuan
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Shen Lian Biomedical announced that the cumulative deviation value of the closing price increase of its stock has exceeded 30% for three consecutive trading days, which constitutes an abnormal fluctuation in stock trading. The company stated that its current main business is veterinary biological products, and the innovative drug pipeline for AIDS monoclonal antibodies is independently operated by its joint venture company Yangzhou Shizhiyuan Biotechnology Co., Ltd. (referred to as "Shizhiyuan"), which has characteristics of long R&D cycles, large investments, and high R&D risks
According to the Zhitong Finance APP, Shen Lian Biomedical (688098.SH) announced that the cumulative price deviation of its stock closing price has exceeded 30% over three consecutive trading days, which constitutes an abnormal fluctuation in stock trading.
The company stated that its current main business is veterinary biological products, and the innovative drug pipeline for AIDS monoclonal antibodies is independently operated by its joint venture Yangzhou Shizhiyuan Biotechnology Co., Ltd. (referred to as "Shizhiyuan"), which has characteristics of long R&D cycles, large investments, and high R&D risks